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Objectives: Aprotinin has been shown to have anti-inflammatory properties, but its
effects on the inflammatory reaction to cardiopulmonary bypass remain controver-
sial. This prospective, randomized, double-blind study evaluated the influence of
aprotinin on various blood markers of inflammation during and after cardiopulmo-
nary bypass.
Methods: Sixty male patients underwent coronary artery bypass grafting. The
patients were randomized into 3 groups: a placebo group, a second group receiving
2,000,000 KIU of aprotinin followed by an infusion of 500,000 KIU/h and
2,000,000 KIU in the pump prime, and a third group receiving half this dosage.
Measurements of tumor necrosis factor, interleukin 6, interleukin 8, interleukin 10,
endotoxin, histamine, complement factors, prekallikrein, and prostaglandin D2 were
obtained at baseline, 30 minutes after study drug loading, 10 minutes after the
beginning of cardiopulmonary bypass, before the end of bypass, 4 hours after
bypass, and on the first and second postoperative days.
Results: Aprotinin had no significant effect on any of these parameters. As expected,
aprotinin reduced early blood loss in both treated groups.
Conclusions: These results indicate that aprotinin at doses currently used to reduce
blood loss has no significant influence on the systemic inflammatory response
during moderate hypothermic cardiopulmonary bypass in human subjects, as as-
sessed by the mediators measured in this study.
Cardiopulmonary bypass (CPB) is associated with a significant in-flammatory reaction characterized by complement activation, lib-eration of endotoxin, cellular activation, and release of cytokinesand other mediators.1-3 Chemotactic cytokines, especially interleu-kin (IL) 8, play a major role in the activation of the inflammatorycascade. Activation of the contact system leads to generation of
kallikrein, which in turn leads to plasmin formation and activation of coagulation.4
This inflammatory response is associated with an anti-inflammatory response,
including the release of IL-10 and tumor necrosis factor (TNF) receptors.5 The
predominant proinflammatory reaction might contribute to postoperative complica-
tions, including the development of postoperative myocardial or other organ dys-
function.6 Different strategies for reducing the inflammatory reaction have been
proposed, including the administration of corticosteroids,7 the use of leukocyte
depletion filters,8 the use of heparin-coated surfaces in the CPB circuits,9 and even
the use of off-pump surgical techniques.10,11
Aprotinin, a serine protease inhibitor now largely used to limit perioperative
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blood loss, has been proposed as another strategy to limit
this inflammatory response by inhibiting some of the pro-
teases involved in the inflammatory activation.2,12-16 Plasma
concentrations of about 200 KIU/mL of aprotinin should be
sufficient to inhibit enzymes like trypsin, plasmin kallikrein,
and elastase.17 In vitro experiments by Soeparwata and
colleagues18 found that aprotinin could limit leukocyte ac-
tivation after CPB. Gilliland and coworkers,19 in an in vitro
model of CPB, showed that aprotinin reduced the expres-
sion of CD18 selectins in granulocytes and monocytes,
although it had no effect on monocyte CD11b or IL-8
plasma concentrations. However, in vitro models of CPB
exclude many of the factors included in the reaction to CPB,
so that extrapolation to clinical CPB should be made with
caution. In a porcine model of CPB, Ali and colleagues20
found that aprotinin was able to reduce capillary leakage
and vasodilation, and recent reports have suggested that
aprotinin might also attenuate the inflammatory reaction to
CPB in human subjects.2,21-23 Aprotinin administration dur-
ing CPB has been shown to inhibit the release of TNF-,
IL-8, and IL-6 and to blunt the CPB-induced upregulation of
CD11b receptors on neutrophils.21,23 However, other inves-
tigators have failed to document an influence of aprotinin on
proinflammatory cytokine release during CPB.24 In view of
these controversial and still fragmented data, the present
study was designed as a prospective, controlled, random-
ized, double-blinded study to evaluate whether aprotinin
can reduce the inflammatory response to CPB.
Patients and Methods
After institutional approval by the ethical committee, 60 adult male
patients weighing between 50 and 90 kg, who were scheduled for
coronary artery bypass graft surgery with at least 2 planned grafts,
were enrolled in the study. One patient was withdrawn from the
study shortly after the surgical procedure because of perioperative
myocardial infarction, requiring immediate reintervention for new
bypass grafting. Accordingly, the randomization procedure was
extended to a 61st patient. Exclusion criteria were severe left
ventricular dysfunction (defined as a left ventricular ejection frac-
tion of 35% or an end-diastolic pressure of 16 mm Hg),
autoimmune disease, a presumed or documented infection, preop-
erative administration of corticosteroids or nonsteroidal anti-
inflammatory medication during the 3 days before the operation,
ingestion of drugs with a known antiplatelet effect (eg, aspirin)
during the 3 days before the operation, emergency procedure,
previous cardiac operation, preoperative hematocrit level of less
than 25%, pre-existing liver dysfunction, pre-existing renal dys-
function (defined as serum creatinine level of 1.7 mg/dL), con-
genital or acquired bleeding disorders, known hypersensitivity to
aprotinin, previous exposure to aprotinin, allergic diathesis or
atopy, or alcohol or drug abuse.
The 60 patients were divided into 3 groups by means of
computerized randomization: (1) a control group that received a
placebo solution; (2) a low-dose group that received a priming
solution of 1,000,000 KIU of aprotinin (Trasylol; Bayer, Le-
verkusen, Germany), followed by a continuous infusion of 250,000
KIU/h and 1,000,000 KIU added to the pump prime; and (3) a
high-dose group that received a priming solution of 2,000,000 KIU
of aprotinin (Trasylol, Bayer), followed by a continuous infusion
of 500,000 KIU/h and 2,000,000 KIU added to the pump prime.
The patients were anesthetized with midazolam and sufentanil
by using a target-controlled infusion generating a plasma concen-
tration of 100 ng/mL midazolam and a plasma concentration of 2
to 4 ng/mL sufentanil.25,26 After induction of anesthesia and ad-
ministration of pancuronium (0.08 mg/kg), the patients were intu-
bated and ventilated with a fraction of inspired oxygen of 0.50, a
respiratory rate of 10 breaths/min, and a tidal volume adjusted to
obtain a PaCO2 of 35 to 40 mm Hg. Each patient was monitored
with a femoral arterial line and a pulmonary artery catheter. The
CPB circuit was primed with a gelatin solution (Haemacel;
Hoechst, Brussels, Belgium), and the flow was adjusted to 2.4
L  min1  kg1. An infusion of phenylephrine (Neo-Synephrine;
Sanofi, Colomiens, France) or sodium nitroprusside (Nitriate;
L’Arguenon Int, Paris, France) was administered when necessary
to maintain a mean arterial pressure of between 60 and 90 mm Hg
during CPB. Arterial blood gases were managed with alpha-stat.
Anterograde cardioplegia was obtained with a cold crystalloid
solution of 800 mL. The patients were cooled to moderate hypo-
thermia of 28°C. Anticoagulation was achieved by using a bolus
dose of 300 IU/kg of porcine heparin (Natrium Heparine; B. Braun
Medical, Jaen, Spain) and additional boluses when necessary to
maintain an activated clotting time with kaolin of greater than
480 s. After CPB, heparin activity was reversed with protamine
(Protamine ICN1000; Sanico, F. Hoffmann-La Roche AG, Kai-
seraugst, Switzerland), assuming a heparin half-life of 60 minutes.
No corticosteroids were administered.
TABLE 1. Clinical data
Control group LD group HD group
Age (y) 61 11 59 11 62 9
Weight (kg) 82.5 5.9 74.3 8.0* 76.2 8.1*
Height (cm) 172 5 171 6 172 6
No. of grafts 3 1 3 1 3 1
Duration of CPB (min) 100 23 107 23 91 25
Duration of aortic clamping (min) 68 13 69 13 60 17
Amount of blood transfused (mL) 662 274 551 256 417 136
*P  .05 versus control group.
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Transfusion requirements and blood loss were recorded. Tho-
racic drainage volume was recorded every 6 hours until the drain
was removed.
Blood samples were obtained from the arterial line at baseline
(before induction of anesthesia), 30 minutes after study drug
loading, 10 minutes after the start of CPB, before the end of CPB,
4 hours after CPB, on the first postoperative day (POD1), and on
the second postoperative day (POD2). Measurements included
TNF-, IL-6, IL-8, IL-10, endotoxin, histamine complement fac-
tors (C1q, C3d, C3, C4, C4a, and C5a), prekallikrein, and prosta-
glandin D2 (PGD2).
After immediate blood centrifugation at 4°C at 3000 rpm for 10
minutes, the plasma was frozen at 80°C. Cytokines were mea-
sured by using immunoenzymometric assays: TNF-, IL-6, IL-8,
and IL-10 were measured with EASIA kits (Medgenix Diagnos-
tics, Fleurus, Belgium). Endotoxin was determined with the Limu-
lus Amebocyte Lysate test (Endosafe, Charleston, SC). Comple-
ment factors C4a and C5a were measured with radioimmunoassays
(Biotrak; Amersham International, Buckinghamshire, United
Kingdom), and complement factors C1q, C3, and C4 were mea-
sured with a nephelometer analyzer (BNII; Behring Dade & Be-
hring, Marburg, Germany). Prekallikrein levels were determined
by using a functional test on the basis of the activation of prekal-
likrein by the presence of an excess of factor XIIA (KABI-Vitrum,
Sweden). PGD2 was measured with an ELISA method (Cayman
Chemical, SPBIO, France).
Sample size was calculated on the basis of the available data on
IL-6 increase during cardiac operations, expecting a mean increase
of about 700 pg/mL with a relative variation of 800% in the
placebo group.5 On the basis of a relevant reduction to 100 pg/mL
with aprotinin, an accepted type 1 error probability  value of .05
(2-sided), an accepted power 1- value of .80, and the assumption
that IL-6 was log normal distributed, a sample size of 20 patients in
each group was necessary. Statistical comparison was done in 2 steps.
First, comparison of high-dose treatment with placebo was per-
formed; when this was significant, the low dose was compared with
placebo. The data were analyzed by means of covariance analysis for
repeated measurements. Variables not normally distributed were an-
alyzed after log transformation. All statistical analyses were per-
formed by Lincoln Systems (Boulogne-Billancourt, France).
Figure 1. Time course of TNF-, IL-6, IL-8, and IL-10 in the 3 groups of patients. CTRL, Control; LD, low dose; HD,
high dose.
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Results
Demographic data are given in Table 1. There was no
significant difference among the 3 groups of patients re-
garding age, height, duration of CPB, aortic crossclamping,
and number of grafts, but the patients in the aprotinin groups
had a lower body weight than those in the placebo group.
There were no significant differences in inflammatory mark-
ers and hemodynamic data at baseline.
The time course of blood cytokine levels is shown in
Figure 1. TNF- and IL-8 levels increased transiently in the
first hours after CPB. IL-6 levels markedly increased after
CPB and remained increased on POD1 and POD2. There
were no significant differences among the 3 groups in
TNF-, IL-6, or IL-8 levels. IL-10 increased to greater than
baseline values at the end of CPB. A tendency toward a
higher value in the placebo group was noted, but because
IL-10 levels were less than the detection threshold in nu-
merous patients, no meaningful statistical analysis could be
done on this value.
Endotoxin levels increased during CPB and returned to
baseline levels on POD1 and POD2 (Table 2). They were
higher in the placebo group than in the treated groups before
the end of CPB, but this was due to one outlying patient who
had a maximum endotoxin increase that was 10 times higher
than that seen in any other patient (560 pg/mL). This patient
had an otherwise uncomplicated postoperative course.
The time course of the complement factors was identical
in all 3 groups (Table 2). C4a levels decreased during CPB
and returned to baseline values after CPB (Figure 2). C5a
levels were stable during the whole procedure. C1q, C3,
C3d, and C4 levels decreased during CPB and increased
after CPB, without returning to their baseline values (Table
2).
Prekallikrein levels decreased sharply at the beginning of
CBP and then increased, without returning to baseline lev-
els. Prekallikrein levels were greater in the high-dose group
than in the other groups only at CPB plus 10 minutes
(Figure 2).
PGD2 levels transiently increased at the end of CPB.
Except for a lower PGD2 level in both treatment groups than
in the placebo group at CPB plus 10 minutes, there were no
significant differences among the 3 groups (Figure 3).
Aprotinin resulted in a reduction in blood loss on the day
of the operation (Figure 3), although overall, there was no
significant difference in the amount of red blood cells or
other blood products transfused (Table 1). No blood prod-
ucts were transfused during CPB. There were no differences
between the groups in the amounts of heparin or protamine
administered. There was no allergic reaction to aprotinin,
and no significant differences among the 3 groups in the
numbers of adverse events, including the most commonly
reported: atrial fibrillation, renal function abnormalities, and
hypoxia.
Discussion
The present placebo-controlled, randomized, double-
blinded trial indicates that aprotinin at doses used clinically
has no significant effect on the release of several inflamma-
tory markers in human subjects during CPB. High-dose, as
well as low-dose, aprotinin has been extensively shown to
TABLE 2. Time course of endotoxin, histamine, and complement factors in the 3 groups of patients
Group Baseline Drug  30 min End CPB CPB  10 min CPB  4 h POD1 POD2
Endotoxin (pg/mL) CTRL 4.5 (2.2-6.9) 6.1 (2.3-31.5) 14.0 (5.0-44.5) 35.5 (15.7-79.4) 20.3 (10.0-75.0) 9.7 (4.2-38.0) 5.7 (2.8-22.6)
LD 4.4 (2.1-9.8) 6.2 (2.8-14.5) 11.7 (5.3-27.7) 23.3 (12.5-43.7) 18.2 (9.2-44.2) 9.4 (5.4-15.7) 5.9 (3.4-16.6)
HD 3.8 (1.8-19.0) 5.7 (3.2-21.8) 10.2 (6.1-30.7) 18.9 (5.6-43.9) 18.0 (6.0-43.1) 9.4 (3.8-32.4) 6.0 (3.7-18.0)
Histamine (mg/dL) CTRL 204 (135-424) 294 (141-644) 76 (0-202) 68 (0-260) 141 (90-224) 184 (122-258) 209 (143-251)
LD 284 (138-735) 287 (169-659) 114 (0-200) 67 (0-211) 213 (122-501) 191 (128-504) 190 (125-443)
HD 230 (164-408) 278 (165-480) 84 (39-173) 79 (0-141) 170 (71-394) 198 (126-309) 224 (116-347)
C1q (mg/dL) CTRL 10 (8-16) 9 (7-14) 5 (3-6) 5 (4-7) 7 (5-8) 4 (3-7) 6 (5-11)
LD 9 (7-11) 9 (6-11) 4 (4-6) 5 (5-7) 7 (5-9) 6 (4-7) 6 (4-9)
HD 9 (7-12) 8 (7-11) 5 (4-5) 6 (5-7) 8 (5-9) 5 (4-8) 6 (3-9)
C3 (mg/dL) CTRL 147 (117-210) 127 (94-159) 59 (48-83) 68 (60-92) 83 (68-105) 73 (60-118) 97 (79-159)
LD 130 (100-167) 109 (83-144) 55 (44-73) 69 (52-92) 85 (62-108) 77 (57-96) 98 (81-123)
HD 130 (112-190) 117 (100-159) 60 (51-75) 76 (61-92) 92 (63-132) 77 (54-112) 88 (65-145)
C3d (mg/dL) CTRL 4.5 (1.9-10.5) 4.7 (1.4-7.1) 2.0 (0.7-4.5) 3.3 (1.2-5.3) 3.8 (1.6-6.2) 2.4 (1.3-4.9) 2.6 (1.5-6.1)
LD 3.8 (1.6-7.7) 3.1 (1.5-7.4) 1.8 (0.9-3.9) 3.0 (1.4-4.8) 2.9 (1.6-5.2) 2.3 (1.0-3.9) 3.2 (1.4-6.3)
HD 5.4 (1.4-10.7) 4.7 (1.0-7.2) 2.2 (0.7-3.9) 3.5 (1.1-5.0) 3.3 (1.6-6.3) 2.6 (0.8-5.2) 3.0 (1.0-6.7)
C4 (mg/dL) CTRL 36 (28-65) 32 (21-50) 12 (8-18) 15 (10-21) 22 (14-32) 18 (12-31) 25 (16-60)
LD 36 (22-56) 29 (18-45) 12 (8-14) 14 (9-19) 20 (15-33) 19 (13-28) 24 (16-37)
HD 31 (22-56) 27 (20-46) 13 (9-15) 15 (11-20) 22 (15-33) 21 (12-32) 22 (14-40)
C5a (mg/dL) CTRL 14 (10-34) 16 (10-20) 15 (10-27) 14 (10-26) 13 (10-41) 10 (10-28) 11 (10-39)
LD 13 (10-21) 12 (10-22) 10 (10-26) 13 (10-32) 13 (10-21) 10 (10-29) 10 (10-23)
HD 14 (10-25) 11 (10-30) 14 (10-27) 12 (10-22) 10 (10-20) 10 (10-25) 11 (10-36)
Values are given as means (25th-75th percentile). CTRL, Control; LD, low dose; HD, high dose.
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reduce bleeding during and after CPB.16,27 In our study also
aprotinin was able to effectively reduce blood losses after
cardiac operations. Although aprotinin did not significantly
influence transfusion requirements, there was a trend toward
increased transfusion in the control group. Importantly,
because transfusion increases cytokine release, the control
group would thus have had increased cytokine levels en-
hancing any apparent anti-inflammatory effects of aprotinin,
but even allowing for this, we were unable to notice any
differences in inflammatory response among the groups.
There are many proposed markers of the inflammatory
response in human subjects, and we selected to measure
several of the key mediators as a guide to the degree of this
response. Although some studies have suggested a relation-
ship between mediator levels and clinical outcomes, this
link has not been firmly established.28,29 In addition, the
degree of mediator release might be influenced by the
preoperative status of the patient and by genetic differences,
such as variations in the TNF allele.30
Endotoxin is often released during CPB, perhaps from
the underperfused gut.31,32 In our study endotoxin levels
were lower in the treated than in the placebo group, but
these differences were due to one outlier in the placebo
group who had a 10-fold maximum increase compared with
that seen in the other patients.
TNF- is synthesized as a membrane-bound precursor
that has to be cleaved to yield soluble TNF proteins, and this
might represent a possible site of action for aprotinin to
inhibit TNF- release. Hill and colleagues21 showed that
even low doses of aprotinin reduced TNF- liberation dur-
ing CPB in human subjects in the same manner as methyl-
prednisolone. Our study showed a significant increase in
TNF- in all 3 groups but no effect of aprotinin on this
process. Recently, another prospective, randomized trial33
in 200 patients undergoing CPB studied the effects of high-
dose aprotinin and heparin-coated circuits. Fifty patients
were randomized to one of 4 groups: heparin-coated circuit
with or without aprotinin and uncoated circuit with or
without aprotinin. The authors of that study33 found that
aprotinin had no effect on levels of TNF-, IL-6, or IL-8.
Aprotinin has been shown in some studies to reduce
other cytokine levels during CPB, namely IL-6 and IL-8,
but these reports are from the studies reporting a lesser
release of TNF-, the major stimulus for release of other
cytokines.21,34 In our study aprotinin failed to inhibit the
increase in IL-6, IL-8, and IL-10 during and after CPB. The
doses used in our study were either equivalent (low-dose
group) or higher (high-dose group) than those in the study
by Hill and colleagues,21 so that dosage does not explain the
different findings. However, the study by Hill and col-
leagues included only 8 patients in each group. Ashraf and
coworkers24 and Gott and associates35 found that aprotinin,
although it inhibited fibrinolysis, had no effect on IL-8
levels in human subjects. IL-10, a major anti-inflammatory
cytokine, is also released during CPB, especially after the
administration of methylprednisolone,5,36,37 and Hill and
Figure 2. Time course of prekallikrein, PGD2, and C4a in the 3
groups of patients. CTRL, Control; LD, low dose; HD, high dose.
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colleagues37 noted that this IL-10 release was enhanced in
patients given aprotinin.
Other aspects of the inflammatory response in addition to
cytokine mediators, including cell factors, complement,
CD11/CD18, and elastase, are also activated during CPB2
and could thus potentially be influenced by aprotinin. Com-
plement activation during CPB is a possible pathway lead-
ing to an increased formation of TNF-.38 Gott and cowork-
ers35 compared 4 anti-inflammatory strategies in CPB, and
in their study only heparin-bonded circuits, but not aproti-
nin, decreased complement activation. In our study comple-
ment system activation was indicated by the decrease in
C1q, C3, and C4 and the increase in C3a after CPB, but
aprotinin had no effect on this process. Activation of the
contact system leads to the formation of kallikrein,39 which
can itself activate the complement system, the bradykinin
system, and proinflammatory cytokine release. Although
aprotinin is able to inhibit the action of kallikrein,40 it had
no consistent effect on prekallikrein levels in our study.
Mast cells are also activated during CPB, and postoper-
ative dysrhythmias in children might be due to histamine
liberation,41 but in our study there was no increase in
histamine levels during CPB. PGD2 is liberated by activated
mast cells,42 but we found no studies that measured PGD2
during and after CPB. Although PGD2 levels were signifi-
cantly lower at the end of CPB in treated patients, these
differences might be due to chance because they were
transient and not dose related.
One might argue that higher doses of aprotinin than that
used in the high-dose regimen in our study might be more
efficient in suppressing the inflammatory response to CPB.
However, the doses we used are those routinely used in
clinical practice. Moreover, the high doses of aprotinin used
in this study have been shown to result in plasma concen-
trations of about 200 KIU/mL, which are sufficient to inhibit
enzymes, such as trypsin, plasmin kallikrein, and elas-
tase.17,21
In conclusion, although aprotinin has some potential for
inhibition of inflammatory pathways, this prospective, ran-
domized, double-blinded trial was unable to demonstrate a
significant effect of even high doses of aprotinin on a
number of key inflammatory mediators during CPB.
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